IN8bio (INAB) News Today $0.33 -0.04 (-10.76%) (As of 11:42 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Short Interest in IN8bio, Inc. (NASDAQ:INAB) Rises By 34.0%December 2 at 3:23 AM | americanbankingnews.comIN8bio's (INAB) Buy Rating Reiterated at HC WainwrightNovember 30 at 2:37 AM | americanbankingnews.comMizuho Securities Remains a Buy on IN8bio (INAB)November 27, 2024 | markets.businessinsider.comIN8bio Presents Positive Clinical Data on INB-200 for Glioblastoma at SNO Annual MeetingOn November 25, 2024, IN8bio, Inc. (NASDAQ: INAB) disclosed significant clinical data from its investigator-sponsored Phase 1 trial of INB-200 for the treatment oNovember 27, 2024 | americanbankingnews.comJonesTrading Sticks to Its Hold Rating for IN8bio (INAB)November 27, 2024 | markets.businessinsider.comINAB: Upcoming Presentations at SNO & ASHNovember 14, 2024 | msn.comIN8bio price target lowered to $8 from $12.50 at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comIN8bio Advances Cancer Therapies Amid Financial RestructuringNovember 14, 2024 | tipranks.comIN8bio, Inc: IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNovember 13, 2024 | finanznachrichten.deIN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNovember 12, 2024 | globenewswire.comIN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual MeetingNovember 12, 2024 | finance.yahoo.comIN8bio files to sell 55.49M shares of common stock for holdersNovember 5, 2024 | markets.businessinsider.comIN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | finance.yahoo.comWall Street Set to Open Lower as Investors Await Earnings Report, Harker SpeechOctober 22, 2024 | msn.comIN8bio (NASDAQ:INAB) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comINAB: Restructuring Narrows Focus to AMLOctober 3, 2024 | finance.yahoo.comIN8bio Announces Pricing of $12.4 Million Private PlacementOctober 1, 2024 | markets.businessinsider.comIN8bio To Cut About 49% Of Jobs, Suspend Glioblastoma Development ProgramSeptember 5, 2024 | markets.businessinsider.comIN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid LeukemiaSeptember 4, 2024 | globenewswire.comIN8bio to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 29, 2024 | globenewswire.comIN8bio, Inc. (6JH.MU)August 23, 2024 | sg.finance.yahoo.comIN8bio Inc (6JH.BE)August 23, 2024 | sg.finance.yahoo.comINAB: AML & GBM Clinical UpdateAugust 14, 2024 | finance.yahoo.comJones Trading Downgrades IN8bio (INAB)August 14, 2024 | msn.comIN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100August 12, 2024 | globenewswire.comINAB Stock Earnings: IN8bio Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comIN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 8, 2024 | finance.yahoo.comIN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 24, 2024 | globenewswire.comIN8bio (NASDAQ:INAB) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $12.50 target price on shares of IN8bio in a research note on Friday.June 14, 2024 | marketbeat.comIN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100June 13, 2024 | globenewswire.comIN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual MeetingJune 3, 2024 | globenewswire.comIN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024May 24, 2024 | globenewswire.comIN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual MeetingMay 23, 2024 | globenewswire.comINAB: 1Q:24 ResultsMay 20, 2024 | finance.yahoo.comIN8bio Announces Upcoming Presentation at 2024 European Hematology Association CongressMay 14, 2024 | globenewswire.comIN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024May 13, 2024 | globenewswire.comBuy Rating Reaffirmed for IN8bio Amid Promising Clinical Trials and Strong PipelineMay 10, 2024 | markets.businessinsider.comIN8bio GAAP EPS of -$0.20 misses by $0.03May 10, 2024 | msn.comINAB Stock Earnings: IN8bio Misses EPS for Q1 2024May 10, 2024 | investorplace.comIN8bio Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 9, 2024 | globenewswire.comIN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed GlioblastomaApril 30, 2024 | globenewswire.comIN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingApril 24, 2024 | globenewswire.comINAB: Initiating Coverage – Enhancing the Insurgents of the Immune SystemApril 22, 2024 | finance.yahoo.comIN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceApril 16, 2024 | globenewswire.comPromising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR PlatformApril 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)April 10, 2024 | markets.businessinsider.comKill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows PotentialApril 10, 2024 | msn.comIN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024April 9, 2024 | globenewswire.comWe're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn RateMarch 28, 2024 | finance.yahoo.comLaidlaw sets INAB stock to buy, targets $7.50 priceMarch 20, 2024 | investing.com Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] INAB Media Mentions By Week INAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INAB News Sentiment▼0.480.87▲Average Medical News Sentiment INAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INAB Articles This Week▼71▲INAB Articles Average Week Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RLMD News Today ANVS News Today ORMP News Today GNLX News Today AVTX News Today TLSA News Today ALGS News Today GNTA News Today NVCT News Today ELYM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INAB) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.